47.8K
Downloads
75
Episodes
AllergyTalk is a round-up of the latest in the field of allergy and immunology by the American College of Allergy, Asthma and Immunology. In each bi-monthly episode, hosts Gerald Lee, MD, and Merin Kalangara, MD, invite a guest to discuss key articles reviewed in the current issue of AllergyWatch.
Episodes
Wednesday Oct 02, 2019
Wednesday Oct 02, 2019
This is part 2 of our summaries from the July-August 2019 issue of Allergy Watch:
Investigation of the factors that determine the severity of allergic reactions to Hymenoptera venoms
https://www.ncbi.nlm.nih.gov/pubmed/30819281
New-Onset Asthma in Adults: What Does the Trigger History Tell Us?
https://www.ncbi.nlm.nih.gov/pubmed/30240884
https://www.ncbi.nlm.nih.gov/pubmed/30277796
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from AstraZeneca.
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.